A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer
- 1Department of Histopathology, Royal Surrey County Hospital and University of Surrey, Guildford, Surrey, UK
- 2Department of Molecular Biology, Royal Surrey County Hospital, Guildford, Surrey, UK
- 3Westmead Hospital, Sydney, New South Wales, Australia
- 4Department of Biomedical Science and Human Oncology, University of Turin, Turin, Italy
- 5Regina Elena Cancer Institute, Rome, Italy
- 6MITERA Maternity and Surgical Center, Athens, Greece
- 7IPATIMUP and Medical Faculty of Porto, Porto, Portugal
- 8University of Tampere, Tampere, Finland
- Silvana Di Palma, Department of Histopathology, Royal Surrey County Hospital, Guildford, Surrey, UK; silvana.dipalma{at}royalsurrey.nhs.uk
- Accepted 11 January 2008
- Published Online First 6 March 2008
Abstract
Background: Chromogenic in situ hybridisation (CISH) is an alternative to immunohistochemistry or FISH for the assessment of HER2 oncogene status in breast cancer. Although CISH is being used increasingly in routine diagnostics, there are no established inter-laboratory quality assurance programmes for this test.
Methods: The reproducibility of HER2 CISH analysis was assessed when performed by seven different centres that use the test routinely in diagnostic service.
Results: The results from 28 cases showed overall concordance of 98.5% (192/195 tests; κ coefficient 0.91). One of the discrepancies was due to the invasive carcinoma having been cut out in the sections received by two of the centres, and the other two were in the non-amplified/equivocal/low-amplified category.
Conclusion: This is believed to be the first report of a quality assurance study assessing laboratories that use HER2 CISH routinely in clinical diagnostics. The results show that CISH is a robust technique providing a suitable assay for the frontline testing of HER2 status in breast cancer.
Footnotes
-
Competing interests: None.
